ATE218342T1 - Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen - Google Patents
Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeenInfo
- Publication number
- ATE218342T1 ATE218342T1 AT98101081T AT98101081T ATE218342T1 AT E218342 T1 ATE218342 T1 AT E218342T1 AT 98101081 T AT98101081 T AT 98101081T AT 98101081 T AT98101081 T AT 98101081T AT E218342 T1 ATE218342 T1 AT E218342T1
- Authority
- AT
- Austria
- Prior art keywords
- cryptosporidiosis
- rifaximin
- treatment
- medication
- diarrhea caused
- Prior art date
Links
- 208000008953 Cryptosporidiosis Diseases 0.000 title abstract 2
- 206010011502 Cryptosporidiosis infection Diseases 0.000 title abstract 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title abstract 2
- 229960003040 rifaximin Drugs 0.000 title abstract 2
- 206010012735 Diarrhoea Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97BO000064A IT1290679B1 (it) | 1997-02-14 | 1997-02-14 | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE218342T1 true ATE218342T1 (de) | 2002-06-15 |
Family
ID=11341939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98101081T ATE218342T1 (de) | 1997-02-14 | 1998-01-22 | Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5886002A (de) |
| EP (1) | EP0858804B1 (de) |
| JP (1) | JP4848083B2 (de) |
| KR (1) | KR100436243B1 (de) |
| CN (1) | CN1115146C (de) |
| AT (1) | ATE218342T1 (de) |
| DE (1) | DE69805672T2 (de) |
| DK (1) | DK0858804T3 (de) |
| ES (1) | ES2178048T3 (de) |
| HU (1) | HU224592B1 (de) |
| IT (1) | IT1290679B1 (de) |
| PT (1) | PT858804E (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| KR20060006953A (ko) * | 2003-04-30 | 2006-01-20 | 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 | 치환된 카르복실산 |
| US20060210483A1 (en) * | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections |
| US20060210492A1 (en) * | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Use of rifaximin for treatment and prevention of periodontal conditions |
| US8003118B2 (en) * | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
| EP1698630B1 (de) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | Neue polymorphe Formen von Rifaximin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| WO2008016708A2 (en) * | 2006-08-02 | 2008-02-07 | Salix Pharmaceuticals, Inc. | Methods for treatment of radiation enteritis |
| US20080161337A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Chronic Prostatitis |
| US20080159987A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Restless Legs Syndrome |
| PT2327407E (pt) | 2008-09-26 | 2014-09-10 | Aska Pharm Co Ltd | Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais |
| DK3628319T3 (da) | 2008-10-02 | 2024-03-04 | Salix Pharmaceuticals Ltd | Behandling af hepatisk encefalopati ved anvendelse af rifaximin |
| US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| US12285414B2 (en) | 2008-10-02 | 2025-04-29 | Salix Pharmaceuticals, Inc. | Methods of treating hepatic encephalopathy |
| AU2010320656B2 (en) | 2009-11-23 | 2015-07-30 | Cipla Limited | Topical foam composition |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| US9211258B2 (en) * | 2010-03-10 | 2015-12-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| EP2616044A1 (de) | 2010-09-13 | 2013-07-24 | Cilpa Limited | Pharmazeutische zusammensetzung |
| WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
| EP3143027B1 (de) | 2014-05-12 | 2019-07-10 | Alfasigma S.p.A. | Neue solvatierte kristallform von rifaximin, produktion, zusammensetzungen und verwendungen davon |
| MX381919B (es) * | 2014-06-30 | 2025-03-13 | Salix Pharmaceuticals Inc | Métodos para repetir tratamiento de síndrome del intestino irritable (ibs). |
| US20180021297A1 (en) * | 2015-02-26 | 2018-01-25 | Jaguar Health, Inc. | Use Of Croton- Or Calophyllum-Derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Non-Human Animals |
| EP3307879A2 (de) * | 2015-06-10 | 2018-04-18 | Synlogic, Inc. | Manipulierte bakterien zur behandlung von krankheiten im zusammenhang mit der hyperammonämie |
| US11224591B2 (en) | 2016-10-14 | 2022-01-18 | Cipla Limited | Pharmaceutical compositions comprising rifaximin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264494B1 (it) * | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
-
1997
- 1997-02-14 IT IT97BO000064A patent/IT1290679B1/it active IP Right Grant
-
1998
- 1998-01-22 DE DE69805672T patent/DE69805672T2/de not_active Expired - Lifetime
- 1998-01-22 AT AT98101081T patent/ATE218342T1/de active
- 1998-01-22 ES ES98101081T patent/ES2178048T3/es not_active Expired - Lifetime
- 1998-01-22 HU HU9800115A patent/HU224592B1/hu active IP Right Grant
- 1998-01-22 EP EP98101081A patent/EP0858804B1/de not_active Expired - Lifetime
- 1998-01-22 DK DK98101081T patent/DK0858804T3/da active
- 1998-01-22 PT PT98101081T patent/PT858804E/pt unknown
- 1998-01-26 US US09/013,655 patent/US5886002A/en not_active Expired - Lifetime
- 1998-02-12 JP JP02981398A patent/JP4848083B2/ja not_active Expired - Lifetime
- 1998-02-13 CN CN98106920A patent/CN1115146C/zh not_active Expired - Lifetime
- 1998-02-13 KR KR10-1998-0004389A patent/KR100436243B1/ko not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ITBO970064A0 (it) | 1997-02-14 |
| HUP9800115A3 (en) | 2000-04-28 |
| JP4848083B2 (ja) | 2011-12-28 |
| DK0858804T3 (da) | 2002-07-08 |
| CN1115146C (zh) | 2003-07-23 |
| EP0858804B1 (de) | 2002-06-05 |
| DE69805672D1 (de) | 2002-07-11 |
| KR100436243B1 (ko) | 2004-08-25 |
| ES2178048T3 (es) | 2002-12-16 |
| EP0858804A1 (de) | 1998-08-19 |
| JPH10226645A (ja) | 1998-08-25 |
| CN1214244A (zh) | 1999-04-21 |
| US5886002A (en) | 1999-03-23 |
| KR19980071348A (ko) | 1998-10-26 |
| IT1290679B1 (it) | 1998-12-10 |
| HUP9800115A1 (hu) | 1999-06-28 |
| PT858804E (pt) | 2002-10-31 |
| HU224592B1 (hu) | 2005-11-28 |
| HU9800115D0 (en) | 1998-03-30 |
| ITBO970064A1 (it) | 1998-08-14 |
| DE69805672T2 (de) | 2003-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE218342T1 (de) | Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen | |
| DE69635959D1 (de) | Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme | |
| ATE212345T1 (de) | Heterocyclische verbindungen und ihre herstellung und verwendung | |
| ATE339968T1 (de) | Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit | |
| DE60237635D1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
| MY131458A (en) | Pyrolopyrimidine compounds | |
| BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
| TR199902538T2 (xx) | Yeni bile�imler. | |
| IL110031A0 (en) | Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them | |
| TR200001203T2 (tr) | Yeni birleşik maddeler | |
| ATE337316T1 (de) | Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen | |
| BR0014381A (pt) | Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência | |
| TNSN98210A1 (fr) | Trifluoromethylethers cycliques a fonction piperidinylaminomethyle, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| ATE235244T1 (de) | Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten | |
| IL104261A0 (en) | Azacyclic and azabicyclic compounds,their preparation and pharmaceutical compositions containing them | |
| ES2195397T3 (es) | Quinazolin-2,4-dionas sustituidas en posicion 7 utiles como agentes antibacterianos. | |
| BR0111989A (pt) | Peptìdeos, composições e processos para o tratamento de burkholderia cepacia | |
| TR200000907T2 (tr) | Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri. | |
| ATE199321T1 (de) | Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen. | |
| ATE212548T1 (de) | Behandlung und prophylaxe von pankreatitis | |
| MX9709451A (es) | Derivados de benzisoxazol e indazol como agentes antipsicoticos. | |
| MA27905A1 (fr) | Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires | |
| HUT73231A (en) | Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis | |
| DE69418353D1 (de) | Cyclische Pentapeptide mit Beta-Turn und Gamma-Turn | |
| DE69820511D1 (de) | Aminosäurederivate und diese enthaltende Zusammensetzungen zur Hemmung von aktivem Sauerstoff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |